Loyal for Dogs, a pioneering veterinary biotech company, announces a breakthrough in the pursuit of extending the lifespan of larger canine breeds. Their latest innovation, LOY-001, targets insulin growth factor-1 (IGF-1), a hormone associated with aging in animals. Aimed at dogs aged 7 and older, weighing over 40 pounds, this drug shows promise in inhibiting IGF-1 to potentially enhance longevity.
In tandem, Loyal is developing two additional versions, LOY-002 and LOY-003, available in convenient daily pill forms, each tailored for specific categories of older dogs. A comprehensive observational study involving 450+ large dogs revealed a correlation between lower insulin levels and reduced frailty, fostering an improved quality of life. The FDA’s recognition of LOY-001’s potential to extend canine lifespans underscores the depth of technical insight driving this groundbreaking development in veterinary medicine.
